An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: We conducted this 6‐week open‐label trial to examine the effects of adjunctive aripiprazole in clozapine‐treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. Method: Ten clozapine‐treated subjects received aripiprazole augmentation; eight completed the 6‐week trial and two ended at week 4. Eighty percent were male, the mean age was 38.7 ± 8.9 years and the mean clozapine dose was 455 ± 83 mg daily. Results: There was a significant decrease in weight ( P = 0.003), body mass index ( P = 0.004), fasting total serum cholesterol ( P = 0.002) and total triglycerides ( P = 0.04) comparing baseline to study endpoint. There was no significant change in total Positive and Negative Syndrome Scale scores. Conclusion: This combination may be useful for clozapine‐associated medical morbidity and must be studied in placebo‐controlled double‐blind randomized trials to determine efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Measurement of fatigue in cancer patients: further validation of the fatigue symptom inventory
Hann, D. M., Denniston, M. M., & Baker, F. (2000) · Quality of Life Research · doi:10.1023/a:1008900413113 · Cited by 258 · cited 2×
“Subjects were assessed with a battery of symptom rating scales at baseline, weeks 2, 4 and 6, including the Positive and Negative Syndrome Scale (PANSS), Scale for Assessment of Negative Symptoms (SANS), Clinical Global Impressions Scale, Hamilton Depression Rating Scale (HAMD), Global Assessment Scale (GAS), Fatigue…”
MethodInfluential
Cited by
Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
Treatment-Resistant Schizophrenia
Elkis, H. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.001 · Cited by 338
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
“The first of these was an open-label study of aripiprazole 15–30 mg daily added to clozapine (mean dose 455 mg/day) for 6 weeks in 13 people with chronic schizophrenia (Henderson et al., 2006).”
BackgroundHenderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288
Self-citationDoes antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.017 · Cited by 252
Metadata
- Authors
- Henderson, D. C., Kunkel, L., Nguyen, D. D., Borba, C. P., Daley, T. B., Louie, P. M., Freudenreich, O., Cather, C., Evins, A. E., & Goff, D. C.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2005-08-24
- Volume
- 113
- Issue
- 2
- Pages
- 142-147
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2077518307
- Cited by
- 114
- References
- 3
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. https://app.cochat.ai/papers/10.1111/j.1600-0447.2005.00612.x
- The paper
- Henderson, D. C., Kunkel, L., Nguyen, D. D., Borba, C. P., Daley, T. B., Louie, P. M., Freudenreich, O., Cather, C., Evins, A. E., & Goff, D. C. (2006). An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2005.00612.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.